Cardiovascular calcification management involves the use of medications and other therapies to treat the buildup of calcium deposits in the arteries and heart valves. Calcification occurs as small deposits of calcium phosphate that accumulate within the intimal layer of arteries or heart valves over many years. This can lead to a narrowing or stiffening of the arteries and impaired heart valve functioning. The calcified deposits do not dissolve on their own and can increase the risk of heart attack and stroke if left untreated. Medications that inhibit calcification progression or promote resorption of existing deposits are commonly prescribed. Chelation therapies are also available to dissolve calcium from arteries. With an aging global population that is more susceptible to age-related calcification, the need for effective management strategies is increasing.
The cardiovascular calcification market is estimated to be valued at USD 125.2 billion in 2024 and is expected to reach USD 174.6 billion by 2031, growing at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.
Key players operating in the cardiovascular calcification management market are Pfizer Inc., Bayer AG, Amgen, Bausch Health Companies Inc., and GE Healthcare.
Key Takeaways
Key players: Pfizer Inc., Bayer AG, and Amgen are considered leaders in the cardiovascular calcification management market given their extensive research and drug portfolios. Pfizer markets medications such as etelcalcetide to treat secondary hyperparathyroidism associated with chronic kidney disease. Bayer's blockbuster lipid-lowering drug Lipitor also helps slow calcification progression in arteries. Meanwhile, Amgen's renal osteodystrophy drugs like Sensipar and Evista demonstrate off-label benefits for Cardiovascular Calcification Market.
Growing demand: The rising global prevalence of conditions linked to cardiovascular calcification like chronic kidney disease, diabetes, and older age drive market growth. These demographic trends are causing healthcare providers to increasingly prioritize early calcification detection and treatment strategies.
Global expansion: Major players are bolstering their international presence through partnerships and new drug approvals to capitalize on the large unmet need across developing regions. For example, GE Healthcare has collaborative deals with hospitals in Asia to promote specialized cardiac CT scan testing.
Explore additional details from the source - The Growing Cardiovascular Calcification Market is Trending due to Increasing CVD Cases Globally
Explore additional details from the source -
Cardiovascular Calcification Management is Estimated to Witness Moderate Growth due to Rising Prevalence of Cardiovascular Diseases